<DOC>
	<DOCNO>NCT00005806</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ZD 1839 give intermittently continuously concurrently standard dos carboplatin paclitaxel patient advance non-small cell lung cancer . II . Determine safety ZD 1839 regimens patient . III . Determine whether exposure either free carboplatin paclitaxel establish treatment regimen significantly alter addition oral ZD 1839 patient population . IV . Determine exposure ZD 1839 standard dose carboplatin paclitaxel ass whether ZD 1839 steady state significantly alter coadministration chemotherapy . OUTLINE : This open label , 2 part , multicenter study . Part 1 randomize , dose escalation , 2 period , 2 sequence , crossover design . Part 2 nonrandomized , single dose evaluation design . Part 1 : Patients randomize receive ZD 1839 begin 1 week either first ( arm I ) second ( arm II ) course carboplatin paclitaxel . Arm I : Patients receive oral ZD 1839 daily day 1-14 . On day 1 , ZD 1839 give twice 12 hour interval . Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 8 36 . Subsequent course consist ZD 1839 14 day paclitaxel carboplatin every 28 day . Arm II : Patients receive paclitaxel carboplatin arm I day 1 29 . Patients receive oral ZD 1839 daily day 22-35 . On day 22 , ZD 1839 give twice 12 hour interval . Subsequent course administer arm I . Part 2 : Patients receive oral ZD 1839 daily day 1-56 . On day 1 , ZD 1839 give twice 12 hour interval . Patients receive paclitaxel carboplatin part 1 day 8 36 . Subsequent course consist ZD 1839 continuously paclitaxel carboplatin every 28 day . Treatment continue part maximum 6 month absence unacceptable toxicity disease progression . In part 1 2 , cohort 6-12 patient receive escalate dos ZD 1839 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 4 6 4 12 patient experience dose limit toxicity . PROJECTED ACCRUAL : A maximum 48 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically and/or cytologically confirm advanced metastatic nonsmall cell lung cancer consider incurable standard surgery irradiation No active brain metastasis indicate clinical symptom , cerebral edema , and/or progressive growth PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 worsen within past 7 day Life expectancy : At least 12 week Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) ALT/AST great 2.5 time ULN ( 5 time ULN liver metastasis ) Renal : Creatinine great 1.25 time ULN No great trace blood protein urine labstix test Cardiovascular : No prior history clinically significant cardiac dysrhythmia , first degree heart block , severe cardiac disease Opthalmologic : No potentially visually threaten epithelial abnormality cornea scar , congenital abnormality , corneal tear film ( e.g. , neurotrophic keratitis , corneal edema , recurrent erosion ) No sign symptom keratoconjunctivitis sicca No concurrent use contact lenses Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except basal cell carcinoma carcinoma situ cervix No evidence severe uncontrolled systemic disease ( e.g. , hepatitis B , hepatitis C , HIV ) No know chronic condition No active dermatosis involve face No evidence significant clinical disorder laboratory find would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy nonsmall cell lung cancer No concurrent biologic response modifier Concurrent filgrastim ( GCSF ) allow persistent neutropenia despite dose reduction prior course Chemotherapy : No prior chemotherapy nonsmall cell lung cancer Endocrine therapy : No concurrent hormonal therapy No concurrent tamoxifen Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Recovered prior oncologic major surgery Other : No concurrent anticancer therapy No concurrent investigational agent No concurrent drug know significant 3A4 inhibitory effect ( i.e. , ketoconazole , itraconazole , troleandomycin , erythromycin , diltiazem , verapamil ) No concurrent hydroxychloroquine , amiodarone , chlorpromazine No concurrent topical eye medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>